It is well known that synthetic peptides are able to both induce and tolerize T cells. We have examined the parameters leading either to priming or tolerance of CD8+ cytotoxic T lymphocytes (CTL) in vivo with a major histocompatibility complex class I (H-2 Db) binding peptide derived from the glycoprotein (GP aa33-41) of lymphocytic choriomeningitis virus (LCMV). By varying dose, route, and frequency of LCMV GP peptide application, we found that a single local subcutaneous injection of 50-500 micrograms peptide emulsified in incomplete Freund's adjuvant protected mice against LCMV infection, whereas repetitive and systemic intraperitoneal application of the same dose caused tolerance of LCMV-specific CTL. The peptide-induced tolerance was transient in euthymic mice but permanent in thymectomized mice. These findings are relevant for a selective use of peptides as a therapeutic approach: peptide-induced priming of T cells for vaccination and peptide-mediated T cell tolerance for intervention in immunopathologies and autoimmune diseases.
Article|
July 01 1995
T cell priming versus T cell tolerance induced by synthetic peptides.
P Aichele,
P Aichele
Institute of Experimental Immunology, University of Zürich, Switzerland.
Search for other works by this author on:
K Brduscha-Riem,
K Brduscha-Riem
Institute of Experimental Immunology, University of Zürich, Switzerland.
Search for other works by this author on:
R M Zinkernagel,
R M Zinkernagel
Institute of Experimental Immunology, University of Zürich, Switzerland.
Search for other works by this author on:
H Hengartner,
H Hengartner
Institute of Experimental Immunology, University of Zürich, Switzerland.
Search for other works by this author on:
H Pircher
H Pircher
Institute of Experimental Immunology, University of Zürich, Switzerland.
Search for other works by this author on:
P Aichele
Institute of Experimental Immunology, University of Zürich, Switzerland.
K Brduscha-Riem
Institute of Experimental Immunology, University of Zürich, Switzerland.
R M Zinkernagel
Institute of Experimental Immunology, University of Zürich, Switzerland.
H Hengartner
Institute of Experimental Immunology, University of Zürich, Switzerland.
H Pircher
Institute of Experimental Immunology, University of Zürich, Switzerland.
Online Issn: 1540-9538
Print Issn: 0022-1007
J Exp Med (1995) 182 (1): 261–266.
Citation
P Aichele, K Brduscha-Riem, R M Zinkernagel, H Hengartner, H Pircher; T cell priming versus T cell tolerance induced by synthetic peptides.. J Exp Med 1 July 1995; 182 (1): 261–266. doi: https://doi.org/10.1084/jem.182.1.261
Download citation file:
Close